Inhibition of human thiopurine S-methyltransferase
by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions.
There is no doubt that the thiopurine S-methyltransferase
(TPMT) gene polymorphism is one of them.
Genotypic analysis of thiopurine S-methyltransferase
in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.
The thiopurine S-methyltransferase
gene locus--implications for clinical pharmacogenomics.
They are cytochrome P450 2D6 and thiopurine S-methyltransferase
They are: 1) the thiopurine S-methyltransferase
(TPMT) deficiency and its relevance to immunosuppression;  and 2) the cytochrome P450-2D6 (CYP2D6) enzyme deficiency and its effect on psychiatric drug therapy.
Molecular diagnosis of thiopurine S-methyltransferase
deficiency: genetic basis for azathioprine and mercaptopurine intolerance.
who investigated 6-thioguanine nucleotide (6-TGN) concentrations in patients with inflammatory bowel disease (IBD), concluded that standard and adapted dosing of azathioprine led to identical 6-TGN concentrations and remission rates and that therapeutic drug monitoring of thiopurine therapy was of no clinical benefit in patients with a wild-type thiopurine S-methyltransferase
First, there is now a commercially available diagnostic test measuring a patient's ability to produce the metabolic enzyme thiopurine S-methyltransferase
(TPMT), which is essential for the metabolism of thiopurine medications used to treat acute lymphoblastic leukemia (ALL), the most common form of childhood cancer.
In addition to the anabolic pathway, 6-MP is catabolized to 6-thiouric acid by xanthine oxidase and to 6-methyl mercaptopurine (6-MMP) by thiopurine S-methyltransferase
For the article entitled "Association of Inosine Triphosphate 94C>A and Thiopurine S-Methyltransferase
Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study", by N.
A large body of evidence suggests that intolerance to therapy is mediated in part by pharmacogenetically relevant polymorphisms in thiopurine S-methyltransferase
(TPMT; EC 2.